著者

Shinichiro Motohashi

出版者

International Society of Personalized Medicne

雑誌

Personalized Medicine Universe (ISSN:21864969)

巻号頁・発行日

vol.11, pp.14-19, 2022-11-01 (Released:2022-11-01)

参考文献数

40

被引用文献数

1

---

Purpose: This review aims to introduce the previous autologous invariant natural killer T (iNKT) cell-targeted cancer immunotherapy and an ongoing clinical trial using allogeneic induced pluripotent stem cell-derived NKT cells (iPS-NKT cells) for head and neck cancer (HNC).Study selection: Combination therapies of adoptive immunotherapy using ex vivo activated iNKT cells derived from cancer-bearing patients and active immunotherapy using ligand-pulsed antigen presenting cells (APCs) are summarized. Since the preparation of functionally sufficient iNKT cells taken from advanced cancer patients was difficult, a robust protocol to generate iNKT cells in vitro via iPS cells was established. Investigator-initiated clinical trials of iPS-NKT cells were also conducted.Results: The combination therapy with α-GalCer-pulsed APCs and adoptive transfer of autologous iNKT cells showed an objective clinical response. An establishment of in vitro generation of iNKT cells from iPS cells allowed us to ensure sufficient expansion of iNKT cells. Based on the preclinical examinations, a phase I study of allogenic iPS-NKT cell monotherapy for advanced or recurrent HNC patients started to test the feasibility and safety of intra-arterial injection of iPS-NKT cells.Conclusions: The clinical study of allogenic iNKT cells is under evaluation. Once the safety profiles of iPS-NKT cell monotherapy are confirmed, we further plan to conduct a combination therapy with iPS-NKT cells plus αGalCer-pulsed APCs. Restimulated iPS-NKT cells are expected to exert potent adjuvant effects and improve anti-tumor responses.